Trials / Completed
CompletedNCT03535363
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
Phase 1 Trial of Osimertinib With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From EGFR Positive Non-Small-Cell Lung Cancer (NSCLC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Case Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Investigating potential of controlling brain metastases in patients with EGFR positive NSCLC.
Detailed description
In patients with EGFR positive NSCLC with 1-10 brain metastases, we are investigating whether we can control the macro brain metastases with Stereotactic Radiosurgery (SRS) and control the micro metastases with targeted agent Osimertinib and avoid whole brain radiation that could potentially lead to significant cognitive decline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Osimertinib | Drug: Osimertinib 80mg or 40mg |
Timeline
- Start date
- 2018-10-26
- Primary completion
- 2022-04-01
- Completion
- 2022-04-01
- First posted
- 2018-05-24
- Last updated
- 2024-03-13
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03535363. Inclusion in this directory is not an endorsement.